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Background: Few clinical trials have evaluated the efficacy and tolerability of antiepileptic drugs (AEDs) as initial
monotherapy for elderly patients.
Methods: This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study
(KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and
controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed
epilepsy. The physician chose VPA or CBZ as preferred standard treatment; patients were randomized to standard
AEDs or LEV. The primary endpoint was time to treatment withdrawal. Results are exploratory, since KOMET was not
powered for a subgroup analysis by age.
Results: Patients (n = 308) were randomized to LEV (n = 48) or VPA-ER (n = 53) in the VPE-ER stratum or to LEV
(n = 104) or CBZ-CR (n = 103) in the CBZ-CR stratum. Mean age was 69.6 years, range 60.2–89.9 years (intention-to-
treat population n = 307). Time to treatment withdrawal hazard ratio [HR] (95 % confidence interval [CI]) for LEV vs.
standard AEDs was 0.44 (0.28–0.67); LEV vs. VPA-ER: 0.46 (0.16–1.33); LEV vs. CBZ-CR: 0.45 (0.28–0.72). Twelve-month
withdrawal rates were: LEV vs. standard AEDs, 20.4 vs. 38.7 %; LEV vs. VPA-ER, 10.4 vs. 23.1 %; LEV vs. CBZ-CR, 25.0 vs.
46.6 %. Time to first seizure was similar between LEV and standard AEDs (HR: 0.92, 95 % CI: 0.63–1.35), LEV and
VPA-ER (0.77, 0.38–1.56), and LEV and CBZ-CR (1.02, 0.64–1.63). Adverse events were reported by 76.2, 67.3, and
82.5 % of patients for LEV, VPA-ER, and CBZ-CR, respectively. Discontinuation rates due to AEs were 11.3, 10.2, and
35.0 % for LEV, VPA-ER, and CBZ-CR, respectively.
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Conclusions: Time to treatment withdrawal was longer with LEV compared with standard AEDs. This finding was
driven primarly by the result in the CBZ-CR stratum, which in turn was likely due to the more favorable tolerability
profile of LEV. Results of this post-hoc analysis suggest that LEV may be a suitable option for initial monotherapy for
patients aged ≥ 60 years with newly diagnosed epilepsy.
Trial registration: ClinicalTrials.gov: NCT00175903; September 9, 2005.
Keywords: Epilepsy, Elderly, Antiepileptic drug, Monotherapy, Levetiracetam
Abbreviations: AE, Adverse event; AED, Antiepileptic drug; CBZ, Carbamazepine; CBZ-CR, Controlled-release
carbamazepine; CI, Confidence interval; EE, Epilepsy in the Elderly; EEG, Electroencephalogram; HR, Hazard ratio;
ITT, Intention-to-treat; KOMET, Keppra vs. Older Monotherapy in Epilepsy Trial; LEV, Levetiracetam; LTG, Lamotrigine;
SANAD, Standard and New Antiepileptic Drugs; STEP-ONE, Study on the Treatment of Elderly Patients with Older
and Newer antiEpileptic Drugs; TEAE, Treatment-emergent adverse event; VPA, Sodium valproate;
VPA-ER, Extended-release sodium valproateBackground
The increased incidence of new-onset epilepsy in the
elderly has been recognized for some time [1–3]. Given
the rapidly aging population, epilepsy in the elderly is
likely to become one of the most frequent forms of epi-
lepsy encountered in clinical practice.
Characteristics of epilepsy, such as etiology, clinical
manifestations, and electroencephalogram (EEG) findings
differ between elderly and younger populations [4–7].
Among the elderly, cerebrovascular disease is the leading
identifiable cause of epilepsy; others include trauma, de-
mentia and brain tumours, typically gliomas, meningi-
omas, and brain metastases [6, 8–10]. However, in a large
number of cases no obvious etiology can be identified
[11]. New-onset seizures in the elderly are typically focal,
with or without secondary generalization, reflecting their
regional etiology and most often their underlying struc-
tural cause [12, 13]. Diagnosis of focal seizures with or
without impairment of consciousness can be challenging
in the elderly, since aura phenomena or automatisms are
less frequent than in younger individuals. Also the period
of postictal confusion can be much prolonged [10, 12].
The choice of antiepileptic drug (AED) for elderly pa-
tients is particularly challenging [4, 5, 12, 14], notably
due to age-related physiological changes which affect
drug pharmacokinetics and pharmacodynamics [15].
The elderly typically have reduced capacity to metabolize
drugs, to excrete drugs via the kidneys, and reduced
plasma protein drug binding due to reduced concentra-
tions of albumin [16, 17]. In addition, there is a correl-
ation between increasing age and the incidence of
adverse drug reactions [18]. AEDs that induce or inhibit
the expression of CYP450 enzymes may affect the me-
tabolism of many commonly prescribed drugs resulting
in clinically relevant drug-drug interactions [4, 5, 8, 19,
20]—this is especially important among elderly patients
who frequently require polytherapy for comorbidities. Ina retrospective study in veterans (≥66 years) with epi-
lepsy, almost half of this population were receiving an
AED that potentially interacted with their existing medi-
cation, most commonly cardiovascular drugs [21].
Despite the important medical need for effective and
well-tolerated AEDs for elderly patients, very few ran-
domized controlled clinical trials have been conducted.
This is predominantly due to challenges inherent in con-
ducting monotherapy trials in epilepsy [22]; difficulties
in recruiting elderly patients, the high number of comor-
bidities and diagnostic complexity also contribute to the
paucity of clinical evidence [9, 23, 24]. Based on these
observations, post-hoc analyses of data from large-scale
clinical studies may be warranted. The Keppra vs. Older
Monotherapy in Epilepsy Trial (KOMET) was a large-
scale, Phase IV trial conducted to compare the effective-
ness of levetiracetam (LEV) with either extended-release
sodium valproate (VPA-ER) or controlled-release carba-
mazepine (CBZ-CR), according to physician choice, in
patients aged ≥ 16 years with newly diagnosed epilepsy
[25]. Like its predecessor, the Standard and New Antiep-
ileptic Drugs (SANAD) trial [26, 27], KOMET was a
pragmatic, randomized trial and, as such, it was not
blinded. Treatment choice—either VPA-ER or CBZ-CR
and subsequent randomization—was based on investiga-
tors’ judgment, which in clinical practice is mainly based
on clarity of diagnosis, seizure type, and patient charac-
teristics. This report presents the results of a post-hoc
subgroup analysis conducted to compare the effective-
ness of LEV with VPA-ER and CBZ-CR among patients
aged ≥ 60 years who participated in KOMET.
Methods
KOMET (N01175; NCT00175903) was a multicenter,
unblinded, randomized, 52-week, controlled superiority
trial with a two-parallel-group design. It was carried
out in a community setting at 269 centers across 23
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2005 and October 2007.
Trial design, methodology, and statistical analysis have
been published [25]. Briefly, patients aged ≥ 16 years
who had experienced two or more unprovoked seizures
in the previous 2 years with at least one during the pre-
vious 6 months were included. At screening, the investi-
gator decided whether VPA or CBZ would be the
standard first-line treatment. Within the VPA stratum,
patients were randomized (1:1) to treatment with LEV
(UCB Pharma, Belgium) or VPA-ER (Sanofi-Aventis,
France). Within the CBZ stratum, patients were random-
ized (1:1) to treatment with LEV or CBZ-CR (Novartis,
Switzerland). Starting doses (LEV 500 mg/day, VPA-ER
500 mg/day, CBZ-CR 200 mg/day) were up-titrated
over 2 weeks to the target doses (LEV 1000 mg/day,
VPA-ER 1000 mg/day, CBZ-CR 600 mg/day). Doses
could be increased to a maximum of LEV 3000 mg/
day, VPA-ER 2000 mg/day, and CBZ-CR 1600 mg/
day, according to the clinician’s judgement.
All participants provided written informed consent be-
fore entering the study. The study was approved by local
ethics committees for every study center. An additional
file shows the full names of all Institutional Review
Boards (see Additional file 1). The study was conducted
in accordance with International Conference on
Harmonisation Good Clinical Practice guidelines and
the Declaration of Helsinki.
Patients
Based on the United Nations’ definition of the elderly [28],
this post-hoc subgroup analysis included all patients who
were aged ≥ 60 years at trial entry. The 60-year cut-off
point for age was also chosen to allow for sufficiently large
patient numbers in each of the treatment groups.
Outcome measures
The primary outcome measure was time to withdrawal
from study medication (treatment withdrawal) calculated
from randomization to the day after the last intake of
study medication. Secondary outcome measures were
time to first seizure calculated from randomization; and
treatment withdrawal and seizure freedom rates at 6 and
12 months. LEV was compared with standard AEDs
(combined VPA and CBZ strata), and with VPA-ER and
CBZ-CR within the individual strata. Results for the
VPA and CBZ strata excluded patients with unclassified
seizure types. Results for each stratum are also reported
for subgroups with only focal or only generalized
seizures (excluding unclassified, unknown or mixed
seizure types). Tolerability was evaluated by documen-
ting treatment-emergent adverse events (TEAEs), their
intensity classified as judged by the investigator (mild,
moderate, or severe) and seriousness.Statistical analysis
All results are exploratory since KOMET was not pow-
ered for a subgroup analysis by age. The intention-to-
treat (ITT) population included all randomized patients,
regardless of actual drug intake. The safety population
consisted of all patients who received one or more doses
of study medication, including those with unknown drug
intake. Patients who were randomized but not treated,
and those who did not give informed consent, were ex-
cluded from the safety population.
Kaplan-Meier survival curves were plotted for time to
treatment withdrawal and time to first seizure. For the
time to treatment withdrawal analysis, all treated pa-
tients who withdrew from the study prior to Day 365
were considered as having the event. Patients who com-
pleted the study or withdrew after Day 365 were cen-
sored at Day 365 or at completion of the study (for
those who completed just prior to Day 365). Untreated
(but randomized) patients were censored at Day 1
(one day after randomization). For the time to first seiz-
ure analysis, patients with no reported seizure during
the 12-month treatment period were censored at the
date of last intake of study medication, date of early ter-
mination, date of Week 52 visit, or Day 364, whichever
was earliest. For the time to treatment withdrawal and
time to first seizure analyses, no further adjustments for
dropouts or missing data were required, as these pa-
tients were censored accordingly.
Time to treatment withdrawal and time to first seizure
were analysed using a Cox’s proportional hazards regres-
sion model including treatment and classification of epi-
lepsy. The treatment effect hazard ratio (HR) was
described using two-sided 95 % confidence intervals
(CIs); a HR of < 1 favored LEV, while a HR of > 1
favoured standard AEDs. Kaplan-Meier survival curves
were plotted for time to treatment withdrawal due to an
AE and calculated from randomization. Since the pri-
mary focus of the post-hoc analysis was on age, a model
was derived from the entire KOMET population, of time
to treatment withdrawal that included the interaction of
treatment and age, and the statistical significance of this
interaction was used as supporting evidence.Results
Overall, 1698 patients were randomized to KOMET, of
whom 308 were aged ≥ 60 years and therefore included
in this analysis (Fig. 1). VPA was deemed by the treating
physicians to be standard treatment for 101 patients
who were subsequently randomized to treatment with
either LEV (n = 48) or VPA-ER (n = 53). Similarly pa-
tients allocated to the CBZ stratum (n = 207) by physi-
cians were subsequently randomised to treatment with
either LEV (n = 104) or CBZ-CR (n = 103). One patient
Patients randomized
ITT population:
ITT population
(N = 307)
Patients allocated to best 
recommended treatment
VPA-ER
(n = 52)
LEV
(n = 104)
Completed
(n = 43; 89.6 %)
Completed
(n = 40; 76.9 %)
Completed
(n = 78; 75.0 %)
Completed
(n = 55; 53.4 %)
CBZ-CR
(n = 103)
LEV
(n = 48)
Discontinued (n = 5; 10.4 %)
•  Adverse event (n = 5)
•  Lack of efficacy (n = 0)
•  Lost to follow-up (n = 0)
•  Withdrawal of consent (n = 0)
•  Other reason (n = 0)
n = 12; 23.1 %
•  n = 5
•  n = 2
•  n = 1
•  n = 3
•  n = 1
n = 26; 25.0 %
•  n = 12
•  n = 6
•  n = 2
•  n = 3
•  n = 3
n = 48; 46.6 %
•  n = 36
•  n = 3
•  n = 2
•  n = 3
•  n = 4
VPA stratum (N = 100) CBZ stratum (N = 207)
Fig. 1 Patient disposition
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population due to no documented informed consent.
At 12 months, retention rates in the VPA stratum were
89.6 % in the LEV group and 76.9 % in the VPA-ER
group. Corresponding values in the CBZ-CR stratum
were 75.0 % and 53.4 % in the LEV and CBZ-CR treat-
ment arms, respectively (Fig. 1).Table 1 Baseline demographics and epilepsy characteristics (intent-
Overall
LEV (n = 152) Standard AEDs (n =
Age, years, mean (SD) 69.5 (6.2) 69.7 (6.4)
Gender, n (%)
Men 85 (55.9) 87 (56.1)
Women 67 (44.1) 68 (43.9)
Number of seizures in the last 2 yearsa,
median (Q1–Q3) [n]
4 (2–6) [150] 4 (2–8) [149]
Epilepsy durationb,
years, median (Q1–Q3)
0.70
(0.27–2.95)
0.70
(0.30–2.12)
Seizure typec, n (%)
Simple focal 30 (19.7) 32 (20.6)
Complex focal 62 (40.8) 62 (40.0)
SG or tonic clonic 84 (55.3) 89 (57.4)
Otherd 4 (2.6) 4 (2.6)
Unclassifiede 5 (3.3) 3 (1.9)
Abbreviations: AED antiepileptic drug, CBZ carbamazepine, CBZ-CR controlled-release
valproate, VPA-ER extended-release sodium valproate
aOverall: LEV, n = 149; standard AEDs, n = 150. CBZ stratum: LEV, n = 102; CBZ-CR, n
bTime since first seizure
cPatients are counted once in each type of seizure experienced
dIncluding absence, myoclonic, clonic, tonic and atonic seizures
eIncluding unclassified, unable to clarify and unknown seizure typesBaseline demographic characteristics were similar for
the LEV and standard AED groups (Table 1). Within the
VPA stratum 36/100 patients (36.0 %) had generalized
seizures only, and within the CBZ stratum 187/207 pa-
tients (90.3 %) had focal seizures only. The majority of
patients had epilepsy either due to an unknown cause
(LEV 56.6 %, standard AEDs 57.4 %) or cerebrovascularto-treat population)
VPA stratum CBZ stratum
155) LEV (n = 48) VPA-ER (n = 52) LEV (n = 104) CBZ-CR (n = 103)
71.1 (6.8) 70.4 (6.5) 68.8 (5.9) 69.3 (6.4)
25 (52.1) 33 (63.5) 60 (57.7) 54 (52.4)
23 (47.9) 19 (36.5) 44 (42.3) 49 (47.6)
3 (2–6) [47] 3 (2–5) [51] 4 (2–8) [102] 4 (3–10) [99]
0.79
(0.20–2.24)
0.73
(0.26–1.84)
0.63
(0.28–3.15)
0.70
(0.32–2.55)
5 (10.4) 4 (7.7) 25 (24.0) 28 (27.2)
15 (31.3) 11 (21.2) 47 (45.2) 51 (49.5)
30 (62.5) 38 (73.1) 54 (51.9) 51 (49.5)
3 (6.3) 3 (5.8) 1 (1.0) 1 (1.0)
4 (8.3) 3 (5.8) 1 (1.0) 0
carbamazepine, LEV levetiracetam, SG secondarily generalised, VPA sodium
= 99. VPA stratum: LEV, n = 47; VPA-ER, n = 51
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jority were also receiving drugs for the management of
cardiovascular disorders (LEV 69.7 %, standard AEDs
75.5 %) including angiotensin converting enzyme inhibi-
tors, statins and beta-blockers.
LEV versus standard AEDs
Time to treatment withdrawal (primary endpoint) was lon-
ger in patients treated with LEV compared with those100
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Fig. 2 Kaplan-Meier survival curves for the time to treatment withdrawal (inte
in the VPA stratum; and c LEV vs. CBZ-CR in the CBZ stratum. Patients with un
strata. Abbreviations: AED antiepileptic drug; CBZ carbamazepine; CBZ-CR cont
VPA-ER extended-release sodium valproatetreated with standard AEDs (HR 0.44, 95 % CI 0.28–0.67)
(Fig. 2a); similarly, treatment withdrawal rates at 6 and 12
months were also lower for LEV-treated patients (Table 2).
Time to first seizure (HR 0.92, 95 % CI 0.63–1.35) [Fig. 3a]
and seizure freedom rates were comparable in both groups
(Table 2). Note: HR of < 1 favors LEV. In the analysis of the
whole KOMET dataset, no difference was observed in time
to treatment withdrawal between LEV and standard AEDs
[25]. However a significant interaction between treatment200
Days
250 300 350 400
200
Days
250 300 350 400
200
Days
250 300 350 400
nt-to-treat population). Legend: a LEV vs. standard AEDs; b LEV vs. VPA-ER
classified seizure types were excluded from analyses for the VPA and CBZ
rolled-release carbamazepine; LEV levetiracetam; VPA sodium valproate;
Table 2 Treatment withdrawal and seizure freedom rates for
levetiracetam and standard antiepileptic drugs (intent-to-treat
population)
Levetiracetam
(n = 152)
Standard antiepileptic drugs
(n = 155)
Treatment withdrawal rate, % (95 % CI)
6 months 14.5 (9.8–21.1) 34.2 (27.3–42.2)
12 months 20.4 (14.8–27.7) 38.7 (31.6–46.9)
Seizure freedom rate, % (95 % CI)
6 months 65.6 (57.1–72.8) 62.9 (53.7–70.7)
12 months 61.8 (53.2–69.3) 59.1 (49.8–67.3)
Abbreviations: CI confidence interval
Pohlmann-Eden et al. BMC Neurology  (2016) 16:149 Page 6 of 12and age (p = 0.002) was identified, indicating that treatment
effect differs with age, supporting the results of the primary
endpoint in the elderly population.
LEV versus VPA-ER
A trend towards longer time to treatment withdrawal
was observed in patients in the LEV group compared
with those in the VPA-ER group (HR 0.46, 95 % CI
0.16–1.33) (Fig. 2b). Correspondingly, estimated treat-
ment withdrawal rates were higher for patients treated
with VPA-ER than LEV at both 6 and 12 months
(Table 3), though the 95 % CIs did not support a dif-
ference between these groups. Time to first seizure was
similar in the LEV and VPA-ER groups (HR 0.77, 95 %
CI 0.38–1.56) (Fig. 3b), as were the estimated 6- and
12-month seizure freedom rates (Table 3). Treatment
withdrawal and seizure freedom rates reported in pa-
tients who only experienced generalized seizures were
similar to those seen for all patients in the VPA stratum
(Table 3). In the analysis of the whole KOMET dataset,
no evidence of an interaction between treatment and
age was found between the VPA-ER and LEV groups
(p = 0.171), in agreement with the analysis in the eld-
erly population.
LEV versus CBZ-CR
Time to treatment withdrawal was longer in patients
treated with LEV compared with those treated with
CBZ-CR (HR 0.45, 95 % CI 0.28–0.72) (Fig. 2c). Esti-
mated 6- and 12-month treatment withdrawal rates were
higher for patients treated with CBZ-CR than LEV
(Table 3). Time to first seizure was similar in the LEV
and CBZ-CR groups (HR 1.02, 95 % CI 0.64–1.63)
(Fig. 3c), as were the estimated 6- and 12-month seizure
freedom rates (Table 3). Treatment withdrawal and seiz-
ure freedom rates reported in patients who only experi-
enced focal seizures were similar to those seen for all
patients in the CBZ stratum (Table 3). In the analysis of
time to withdrawal in the whole KOMET dataset, the
interaction between treatment and age was significant(p = 0.009), supporting the comparison of LEV and CBZ-
CR in the elderly population.
Safety and tolerability
At least one TEAE was reported by 76.2 % of patients
treated with LEV (both strata combined) compared with
VPA-ER (67.3 %) and CBZ-CR (82.5 %) [Table 4]. Higher
incidences of severe AEs were reported in the LEV
(20.5 %) and CBZ-CR (17. 5 %) groups than in the VPA-
ER group (8.2 %). Although serious AEs were more fre-
quently reported by patients treated with LEV (18.5 %)
than CBZ-CR (10.7 %) or VPA-ER (4.1 %), drug-related
serious AEs had a comparably low incidence in all
groups (2.0 %, 2.9 %, and 2.0 %, respectively).
TEAEs most commonly reported (≥10 % of patients)
were fatigue (11.3 %) with LEV; fatigue (18.4 %), tremor
(14.3 %), and weight gain (12.2 %) with VPA-ER; and fa-
tigue (23.3 %) and dizziness (15.5 %) with CBZ-CR
(Table 4).
Time to treatment withdrawal due to AEs was lon-
ger for LEV than for standard AEDs (HR 0.36, 95 %
CI 0.20–0.63) (Fig. 4). In the safety population, more
patients treated with standard AEDs discontinued
treatment due to AEs than those treated with LEV
(27.0 % vs. 11.3 %); mostly due to the higher propor-
tion of withdrawals in the CBZ-CR group (35.0 %)
(Table 4).
Three deaths were reported; two patients treated with
LEV (head injury sustained in road traffic accident; radi-
ation injury) and one treated with CBZ-CR (acute myo-
cardial infarction). None of the deaths were considered
to be related to study medication.
Discussion
This post-hoc subgroup analysis of data from KOMET,
an unblinded, randomized trial [25], compared the ef-
fectiveness of LEV with that of standard AEDs among
patients aged ≥ 60 years with newly diagnosed epilepsy.
Consistent with existing data [13, 29, 30] and in keep-
ing with acquired focal brain pathology in the elderly,
the majority of patients included in this analysis experi-
enced focal seizures, of which complex focal (automo-
tor) seizures were more frequent than simple focal
seizures. The most frequent identifiable causes of epi-
lepsy were cerebrovascular, also consistent with previ-
ous observations [6, 8, 10, 14, 31]. The majority of
patients were allocated to CBZ as standard treatment,
although as many as one-third were allocated to the
VPA stratum. It is important to note that KOMET was
a pragmatic trial, and that choice of treatment was not
determined by protocol, but by the treating physicians.
Consequently, not all patients may have received what
is considered standard treatment; indeed, robust evi-
dence for a standard treatment is lacking in the elderly.
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Fig. 3 Kaplan-Meier survival curves for the time to first seizure (intent-to-treat population). Legend: a LEV vs. standard AEDs; b LEV vs. VPA-ER in the
VPA stratum; and c LEV vs. CBZ-CR in the CBZ stratum. Patients with unclassified seizure types were excluded from analyses for the VPA and CBZ strata.
Abbreviations: AED antiepileptic drug; CBZ carbamazepine; CBZ-CR controlled-release carbamazepine; LEV levetiracetam; VPA sodium valproate; VPA-ER
extended-release sodium valproate
Pohlmann-Eden et al. BMC Neurology  (2016) 16:149 Page 7 of 12Furthermore, diagnosis of epilepsy and classification of
seizure type in the elderly population present signifi-
cant challenges. Among patients thought to have gener-
alized seizures, some may actually have had secondary
generalized seizures and arguably, once again, were not
allocated standard treatment. At the time KOMET was
conducted, VPA was commonly prescribed for older
people due to its broad therapeutic spectrum and
straightforward dosing schedule [6, 32–34]. In contrast,CBZ can be difficult to use in the elderly because as an
enzyme inducer, it has strong potential for drug-drug
interactions, adverse impact on bone health [19, 33,
35], lipids and cardiovascular risk [36, 37], and influ-
ence on cardiac conduction systems [6]; all important
concerns in this population.
Overall, LEV showed an advantage over standard
AEDs in the elderly subpopulation, as demonstrated by a
longer time to treatment withdrawal. The difference was
Table 3 Treatment withdrawal and seizure freedom rates (Kaplan-Meier estimates) for sodium valproate and carbamazepine strata
(intent-to-treat population)a
Sodium valproate stratum LEV VPA-ER
All seizure types n = 48 All seizure types n = 52
Generalized seizures only n = 14 Generalized seizures only n = 22
Treatment withdrawal rate, % (95 % CI)
6 months All seizure types 4.2 (1.1–15.7) 19.2 (10.8–32.8)
Generalized seizures only 7.1 (1.0–40.9) 18.2 (7.2–41.5)
12 months All seizure types 10.4 (4.5–23.2) 23.1 (13.8–37.0)
Generalized seizures only 14.3 (3.8–46.1) 22.7 (10.2–46.3)
Seizure freedom rate, % (95 % CI)
6 months All seizure types 70.4 (55.1–81.3) 63.4 (47.8–75.4)
Generalized seizures only 69.6 (37.8–87.4) 63.3 (38.1–80.6)
12 months All seizure types 66.0 (50.5–77.6) 59.0 (43.5–71.6)
Generalized seizures only – 52.8 (28.9–72.0)
Carbamazepine stratum LEV CBZ-CR
All seizure types n = 104 All seizure types n = 103
Focal seizures only n = 93 Focal seizures only n = 94
Treatment withdrawal rate, % (95 % CI)
6 months All seizure types 19.2 (12.9–28.2) 41.8 (32.9–51.9)
Focal seizures only 18.3 (11.8–27.8) 40.4 (31.3–51.1)
12 months All seizure types 25.0 (17.8–34.5) 46.6 (37.6–56.7)
Focal seizures only 24.7 (17.2–34.8) 45.8 (36.4–56.4)
Seizure freedom rate, % (95 % CI)
6 months All seizure types 63.3 (52.6–72.1) 63.2 (51.4–72.8)
Focal seizures only 59.3 (48.0–68.9) 63.1 (51.0–73.1)
12 months All seizure types 59.8 (49.1–69.0) 59.8 (47.7–69.9)
Focal seizures only 55.5 (44.2–65.4) 61.3 (49.0–71.5)
Abbreviations: CBZ-CR controlled-release carbamazepine, CI confidence interval, LEV levetiracetam, VPA-ER extended-release sodium valproate
aFor the sodium valproate stratum, data are presented for all patients (intent-to-treat population excluding unclassified seizure types) and those with generalized
seizures only (intent-to-treat population excluding unclassified, unknown and mixed seizure types). For the carbamazepine stratum, data are presented for all
patients (intent-to-treat population excluding unclassified seizure types) and those with focal seizures only (intent-to-treat population excluding unclassified,
unknown and mixed seizure types)
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as shown in the analysis of the individual strata. While
time to treatment withdrawal was longer with LEV com-
pared with CBZ-CR in the CBZ stratum, this was not
the case in the VPA stratum. However, patients treated
with LEV showed a potential advantage over those
treated with VPA-ER in that the proportion of patients
who withdrew from treatment at 12 months was greater
with VPA-ER than with LEV (22.7 % vs. 14.3 % for patients
with generalized seizures only; 23.1 % vs. 10.4 % for pa-
tients with all types of seizures). Treatment withdrawal
rates at 12 months were also greater for elderly patients
treated with CBZ-CR compared with those treated with
LEV in the CBZ stratum and for standard AEDs in the
overall comparison with LEV. Analysis of the interaction
between treatment and age in time to treatment withdrawalusing data from the entire KOMET population supported
the results observed in this elderly subpopulation. A signifi-
cant interaction between treatment and age was identified
in the overall comparison, suggesting that the response to
LEV or standard AEDs did indeed differ according to age.
The interaction was also significant in the CBZ stratum,
but not in the VPA stratum, once again reflecting the re-
sults of this subgroup analysis in elderly patients.
Time to first seizure analysis suggested similarity be-
tween LEV and standard AEDs, and between LEV and
CBZ-CR or VPA-ER in the individual strata. Approxi-
mately one-third of the elderly patients who were
allocated to the VPA stratum experienced generalized
seizures only, predominantly tonic-clonc; results for this
group of patients were similar to the overall results for the
VPA stratum. Correspondingly, results for patients
Table 4 Summary of treatment-emergent adverse events (safety population)
All patients
LEV (n = 151) Standard AEDs (n = 152) VPA-ER (n = 49) CBZ-CR (n = 103)
Summary of adverse events, n (%)
≥1 TEAE 115 (76.2) 118 (77.6) 33 (67.3) 85 (82.5)
Drug-related AEs 70 (46.4) 93 (61.2) 29 (59.2) 64 (62.1)
Severe AEsa 31 (20.5) 22 (14.5) 4 (8.2) 18 (17.5)
Serious AEs 28 (18.5) 13 (8.6) 2 (4.1) 11 (10.7)
Serious drug-related AEs 3 (2.0) 4 (2.6) 1 (2.0) 3 (2.9)
AEs leading to discontinuation 17 (11.3) 41 (27.0) 5 (10.2) 36 (35.0)
Deaths 2 (1.3) 1 (0.7) 0 1 (1.0)
Drug-related TEAEs reported by ≥ 5 % of patients in any treatment group, n (%)
Fatigue 17 (11.3) 33 (21.7) 9 (18.4) 24 (23.3)
Dizziness 10 (6.6) 16 (10.5) 0 16 (15.5)
Somnolence 8 (5.3) 9 (5.9) 2 (4.1) 7 (6.8)
Headache 8 (5.3) 7 (4.6) 0 7 (6.8)
Nausea 4 (2.6) 11 (7.2) 1 (2.0) 10 (9.7)
Weight gain 4 (2.6) 11 (7.2) 6 (12.2) 5 (4.9)
Tremor 1 (0.7) 9 (5.9) 7 (14.3) 2 (1.9)
Constipation 1 (0.7) 6 (3.9) 0 6 (5.8)
Rash 0 8 (5.3) 0 8 (7.8)
Abbreviations: AE adverse event, AED antiepileptic drug, CBZ carbamazepine, CBZ-CR controlled-release carbamazepine, LEV levetiracetam, TEAE treatment-
emergent adverse event, VPA sodium valproate, VPA-ER extended-release sodium valproate
aSevere AEs were those affecting the patient’s ability to work normally or to carry out usual activities, and those of definite clinical consequence
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seizures were similar to the overall results for this
stratum.
With regard to tolerability, the time to treatment with-
drawal due to AEs was longer in patients treated with
LEV compared with standard AEDs. In particular, the
discontinuation rate for patients randomized to CBZ-CR
was higher than that for patients taking LEV or VPA-ER.
However, it should be noted that the initial target dose
of CBZ-CR (600 mg/day) may have been too high and100
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due to AEs in the CBZ-CR group in KOMET overall
(18.8 %) and this subgroup analysis (35.0 %) indicates
that the target dose of CBZ-CR was tolerated better by
younger patients. Differences in withdrawal rates due to
AEs between KOMET overall and the elderly subgroup
were less pronounced for LEV (8.3 % vs. 11.3 %; safety
population) and VPA-ER (4.7 % vs. 10.2 %; safety200
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that the difference between LEV and standard AEDs in
the overall time to treatment withdrawal may be largely
explained by differences in tolerability.
The main trial, KOMET, included 1688 patients
(intention-to-treat population) with an overall mean age
of 41 years [25]. Regarding time to treatment with-
drawal, KOMET reported that LEV monotherapy was
not superior to standard AEDs overall (HR 0.90, 95 % CI
0.74–1.08) or in the individual strata vs. VPA-ER (HR
1.02, 95 % CI 0.74–1.41) and CBZ-CR (HR 0.84, 95 % CI
0.66–1.07). In contrast, in this subgroup analysis of eld-
erly patients, time to treatment withdrawal was longer
for LEV compared with standard AEDs (HR 0.44, 95 %
CI 0.28–0.67) and CBZ-CR (HR 0.45, 95 % CI 0.28–
0.72), but not VPA-ER (HR 0.46, 95 % CI 0.16–1.33).
Conversely, time to first seizure was longer for standard
AEDs compared with LEV in KOMET overall (HR 1.20,
95 % CI 1.03–1.39), but not in the elderly subgroup (HR
0.92, 95 % CI 0.63–1.35).
Interpretation of these findings should take into ac-
count that this was a post-hoc subgroup analysis of data
from a larger trial. In considering these results, it should
be noted that approximately twice as many elderly pa-
tients were assigned to the CBZ stratum vs. the VPA
stratum. As a pragmatic trial, KOMET had a number of
limitations, including patient selection and treatment al-
location at the discretion of the physician, and unblinded
treatment. Another major limitation is the lack of neuro-
imaging information with regard to underlying etiology,
which likely has a major prognostic impact in this spe-
cific epilepsy population [38]. We challenge the term
Epilepsy in the Elderly (EE), which refers to people older
than 60 years. The term is likely to be conceptually ir-
relevant for disease management and prognosis [39],
since biological age, as reflected in imaging findings, is
more important than chronological age. In a recent pro-
spective new-onset population, the underlying MRI-
proven lesions were not significantly different in the EE
group compared with patients aged between 50 and
60 years [39].
To date, five randomized, controlled trials of AED
monotherapy have been conducted in elderly patients
with newly diagnosed epilepsy [30, 31, 40–42]. In gen-
eral, results have indicated that the AEDs tested in the
trials have comparable efficacy in this population, but
differing tolerability profiles. Four trials reported com-
parable efficacy between LTG and CBZ in terms of time
to first seizure [40] or seizure freedom [30, 41, 42].
However, retention rates were higher for LTG than CBZ
in the four trials, largely attributed to better tolerability
with LTG. The Study on the Treatment of Elderly
Patients with Older and Newer antiEpileptic drugs
(STEP-ONE) trial was the first prospective, randomized,double-blind trial to compare LEV and LTG with CBZ-
CR in elderly patients with newly diagnosed epilepsy.
The results indicated that the efficacy of LEV monother-
apy was similar to that of CBZ-CR, while tolerability was
superior, leading to significantly greater effectiveness in
terms of retention rate [31]. Our findings from this sub-
group analysis of the KOMET study are in agreement
with those from STEP-ONE, and provide further sup-
porting evidence for the use of LEV monotherapy for
elderly patients with newly diagnosed epilepsy.
Conclusions
In this post-hoc analysis of data from KOMET, time to
treatment withdrawal was longer with LEV than with
standard AEDs. Since time to treatment withdrawal was
similar between LEV and VPA-ER, the overall result was
driven mainly by the results in the CBZ-CR stratum. Pa-
tients remained in the LEV treatment arm longer than
those in the CBZ-CR arm, most likely because of the
better tolerability of LEV. While the tolerability of CBZ-
CR could have been improved by using a lower starting
dose and slower up-titration, the long-term use of CBZ-
CR in the elderly population is problematic in light of its
enzyme-inducing properties. The results of this analysis
are in agreement with those of the randomized, double-
blind STEP-ONE trial and several prospective, observa-
tional studies. Consequently, LEV may be considered a
suitable option as initial monotherapy for individuals
aged 60 years or above with newly diagnosed epilepsy.
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